FDA advances Precision Medicine Initiative by issuing draft guidances on next generation sequencing-based tests

FDAIn support of the President’s Precision Medicine Initiative, the U.S. Food and Drug Administration has issued two draft guidances that, when finalized, will provide a flexible and streamlined approach to the oversight of tests that detect medically important differences in a person's genomic makeup.

The powerful new technology, known as next generation sequencing (NGS), can scan a person's DNA to detect genomic variations that may determine whether a person has or is at risk of disease or may help to inform treatment decisions. While current regulatory approaches are appropriate for conventional diagnostics that measure a limited number of substances associated with a disease or condition, such as blood glucose or cholesterol levels, the new sequencing technologies can examine millions of DNA variants at a time, and thus require a flexible approach to oversight that is adapted to the novel nature of these tests.

"Targeting the right treatments to the right patients at the right time is the goal of the President’s Precision Medicine Initiative," said FDA Commissioner Robert Califf, M.D. "Soon, patients will have a much more complete picture of their health than in the past, informed by their genetic and genomic makeup. The FDA is preparing for this exciting approach at multiple levels."

The field of genetic and genomic testing is dynamic, and the agency understands that there is a need to encourage innovation while assuring that NGS-based tests provide accurate and useful results. When the guidances are finalized, adherence to them will offer appropriate flexible and adaptive regulatory oversight of these tests, while allowing for variations in development and validation and accommodating the rapid evolution of NGS technologies.

"The FDA values the input we received from genomics experts, industry, health care providers and patients from four public workshops and other outreach opportunities. Based on this input, we crafted draft recommendations that we believe will encourage innovation and advance the goal of precision medicine: to speed the right individualized treatments to patients sooner," said Jeffrey Shuren, M.D., J.D., director of the FDA's Center for Devices and Radiological Health. "Precision care is only as good as the tests that guide diagnosis and treatment. The FDA's job is to ensure that doctors and patients can depend upon the accuracy, reliability and clinical validity of these tests. It’s our hope that this approach will achieve just that."

The first draft guidance, titled "Use of Standards in FDA’s Regulatory Oversight of Next Generation Sequencing (NGS)-Based In Vitro Diagnostics (IVDs) Used for Diagnosing Germline Diseases" provides recommendations for designing, developing and validating NGS-based tests for rare hereditary diseases, and addresses the potential for using FDA-recognized standards to demonstrate analytical validity, which is how well a test predicts the presence or absence of a particular genomic change.

The second draft guidance, titled "Use of Public Human Genetic Variant Databases to Support Clinical Validity for Next Generation Sequencing (NGS)-Based In Vitro Diagnostics" describes an approach wherein test developers may rely on clinical evidence from FDA-recognized public genome databases to support clinical claims for their tests and provide assurance of accurate clinical interpretation of genomic test results - an easier path for marketing clearance or approval.

"The draft guidances are an important step in the development of NGS-based tests," said Francis Collins, M.D., Ph.D., director of the National Institutes of Health (NIH). "NIH sees great value in these guidances and encourages test developers to adopt the best practices outlined in the guidances so that high quality tests can become available to the patients who need them."

This adaptive approach to regulating NGS-based tests is part of the FDA’s engagement in the Precision Medicine Initiative (PMI). The PMI, launched by the White House in early 2015, is an innovative approach to developing a new kind of health care that takes into account individual differences in people's genes, environments and lifestyles. The FDA’s role in the PMI is foundational: to create regulatory processes that encourage advances in genomic testing while assuring that NGS-based tests are safe and effective. The FDA has been working with experts in the genomics community to conceptualize this flexible approach that strikes the important balance between safeguarding public health and promoting innovation.

The FDA encourages public comments on the draft guidances during the 90-day comment period.

The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation's food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.

Most Popular Now

Bayer Thrombosis Research Award 2019 goes to Dr. C…

The fourth winner of the Bayer Thrombosis Research Award has been chosen. The Scientific Committee of the Bayer Science & Education Foundation awarded the EUR 30,000 priz...

Roche enters into definitive merger agreement to a…

Roche (SIX: RO, ROG; OTCQX: RHHBY) and Spark Therapeutics, Inc. (NASDAQ: ONCE) have entered into a definitive merger agreement for Roche to fully acquire Spark Therapeuti...

Brilinta’s Phase III THEMIS trial met primary endp…

The Phase III THEMIS trial met its primary endpoint and demonstrated that Brilinta (ticagrelor), taken in conjunction with aspirin, showed a statistically-significant red...

Jury upholds Amgen's patents on Repatha® (evolocum…

Amgen (NASDAQ:AMGN) announced that a Delaware jury delivered a verdict in Amgen's favor upholding the validity of two Amgen patents related to PCSK9 antibodies. These pat...

Protein content as a marker for response to therap…

Brain tumors vary widely in how they respond to treatment. However, early assessment of therapy response is essential in order to choose the best possible treatment for t...

Artificial lung cancer tissue could help find new …

A 3D hydrogel created by researchers in U of T Engineering Professor Molly Shoichet's lab is helping University of Ottawa researchers to quickly screen hundreds of potent...

Could medical marijuana help grandma and grandpa w…

Medical marijuana may bring relief to older people who have symptoms like pain, sleep disorders or anxiety due to chronic conditions including amyotrophic lateral scleros...

New treatment offers potentially promising results…

A pioneering clinical trials program that delivered an experimental treatment directly to the brain offers hope that it may be possible to restore the cells damaged in Pa...

Amgen, Cytokinetics and Servier announce start of …

Amgen (NASDAQ: AMGN), Cytokinetics, Incorporated (NASDAQ: CYTK) and Servier today announced that METEORIC-HF (Multicenter Exercise Tolerance Evaluation of Omecamtiv Mecar...

Could blockchain ensure integrity of clinical tria…

UC San Francisco researchers have created a proof-of-concept method for ensuring the integrity of clinical trials data with blockchain. The system creates an immutable au...

Novartis data confirm rapid response and high effi…

Novartis announced today new data in 441 Chinese patients with moderate to severe plaque psoriasis from a Phase III study investigating the efficacy and safety of Cosenty...

Abbott and Novo Nordisk enter partnership to provi…

Abbott and Novo Nordisk today announced a non-exclusive partnership that will integrate insulin dose data from Novo Nordisk pre-filled and durable connected pens directly...